Search results
Showing 8056 to 8070 of 8981 results
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]
In development Reference number: GID-TA11481 Expected publication date: TBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
In development Reference number: GID-TA11528 Expected publication date: TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Discontinued Reference number: GID-TA10995
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
In development Reference number: GID-TA10774 Expected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development Reference number: GID-TA10886 Expected publication date: TBC
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]
Discontinued Reference number: GID-TA10897
Palforzia for treating peanut allergy in children and young people (TA769)
NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Discontinued Reference number: GID-TA10637
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Discontinued Reference number: GID-TA10722
Discontinued Reference number: GID-TA10308
Discontinued Reference number: GID-TA10019
Discontinued Reference number: GID-NG10168
Discontinued Reference number: GID-TA10698
Discontinued Reference number: GID-TA10166